Fresh frozen plasma transfusion after cardiac surgery.

ABSTRACT

INTRODUCTION: Fresh frozen plasma (FFP) transfusion in the intensive care unit (ICU) is commonly used to treat coagulopathy and bleeding in cardiac surgery, despite suggestion that it may increase the risk of morbidity and mortality through mechanisms such as fluid overload and infection. METHODS: We retrospectively studied consecutive adults undergoing cardiac surgery from the Medical Information Mart for Intensive Care III and IV databases. We applied propensity score matching to investigate the independent association of within-ICU FFP transfusion with mortality and other key clinical outcomes. RESULTS: Of our 12,043 adults who met inclusion criteria, 1585 (13.2%) received perioperative FFP with a median of 2.48 units per recipient (interquartile range [IQR] 2.04, 4.33) at a median time of 1.83 h (IQR 0.75, 3.75) after ICU admission. After propensity matching of 952 FFP recipients to 952 controls, we found no significant association between FFP use and hospital mortality (odds ratio (OR) 1.58; 99% confidence interval (CI) 0.57, 3.71), suspected infection (OR 0.72; 99% CI 0.49, 1.08), or acute kidney injury (OR 1.23; 99% CI 0.91, 1.67). However, FFP was associated with increased days in hospital (adjusted mean difference (AMD) 1.28; 99% CI 0.27, 2.41; p = .0050), days in intensive care (AMD 1.28; 99% CI 0.27, 2.28; p = .0011), and chest tube output in millilitres up to 8 h after transfusion (AMD 92.98; 99% CI 52.22, 133.74; p < .0001). CONCLUSIONS: After propensity matching, FFP transfusion was not associated with increased hospital mortality, but was associated with increased length of stay and no decrease in bleeding in the early post-transfusion period.